The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
about
The EMPA-REG outcome study: critical appraisal and potential clinical implicationsEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusIncretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart diseaseSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic ReviewSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsComparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysisImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureThe Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart FailureEfficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsRationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.Empagliflozin in the treatment of type 2 diabetes: evidence to dateThe sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicityHigher blood aldosterone level in metabolic syndrome is independently related to adiposity and fasting plasma glucose.Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient.SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis.Aspects of Hyperglycemia Contribution to Arterial Stiffness and Cardiovascular Complications in Patients With Type 1 Diabetes.Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 DiabetesA randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysisEarly changes in cardiovascular structure and function in adolescents with type 1 diabetes.The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusCardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice.Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.Empagliflozin for the treatment of type 2 diabetes.
P2860
Q26748742-50602F46-DBFA-4B63-A73B-EEBD6E2DDFFFQ26782225-691AB084-EC1D-44C2-9D07-4D23B7942BCFQ26784211-661F2D71-43EC-4126-A469-100DEA51CF27Q28072352-77F672C6-51F3-40F3-888B-A03B9ED89322Q28072765-B9F98A58-D503-4010-8AB9-6D4D82261175Q28074573-D525A2E9-F847-43FA-B226-B8DA82658DECQ28080114-F051353C-6274-45C6-9E39-F6E79451B1AAQ28082343-3224EAD8-953E-4B41-94F4-D76233B5068FQ31105792-A11EEB6F-51F1-4922-B8C2-635AB0A74FFAQ31112303-2D57D384-FED2-4CAA-8B9B-74A699C2C11DQ33556240-CC54A2E7-9C44-483B-8703-A8E680900AD6Q33625568-9B2E8BC5-8F82-478E-AB71-ECCE14FFE875Q33812170-B7E4F0FD-35A0-4B0C-85AF-E56B8207EABFQ33882438-3B19E175-D5FC-4C48-9538-B461B7BBC7A1Q34502358-C05D3EC2-6F17-4CE4-ABEF-DC62031E3965Q34524690-7DE332EF-1849-4253-BE7B-9242DD351B6EQ34997841-4EB7A157-F54E-435E-A60A-9FB10A30AE1DQ35133751-683E5B65-3D16-4F8C-AC5A-5BE0A2319545Q35181821-6928CA1B-02CF-43FB-9F75-D0997B32C518Q35784776-ABDBD4C3-2E6B-476C-8BE2-63FF93281B42Q35950003-AC09964F-1034-4040-86DB-8A6260CCB0CDQ36069685-BF8BAE1B-C25E-49C0-A50A-3D3D0283D821Q36144090-8929E500-7E8E-4211-AF35-E2531A5C65CEQ36257199-1B7E62CB-6195-458D-97F6-9103B22EFD55Q36288929-BB28B6D8-C56F-476C-AA89-EDFA8BA3F5C6Q36301818-266AF8F5-7B4B-4CA6-AB65-64D78F9531EBQ36583611-B7F6BADE-E35C-48DF-A0EE-1103CD02C4C1Q36592820-2B472A96-9AF3-48EB-8F58-4A85CBF5E14FQ36599869-37E517D9-911A-4049-B371-63FC94A00557Q36820604-3204E887-2BE8-46FA-80AE-DFACF5F210DEQ36926197-503A9511-3214-4DA8-B133-5255B683B168Q36937697-53A79A5C-3B1D-4E2A-B2CD-7CFC765FEA21Q37097189-828AE40C-99A5-4750-A64D-872EB286F558Q37251449-6D119135-CDAA-4AA4-A656-CB4A3CF2CD1AQ37325818-4D5268B2-9E6D-481C-A2EF-6EB1549AE604Q37390839-FD412536-9854-42B5-A806-79C39770F765Q37559899-711FBC13-3A23-4820-A514-73F9FCA802D1Q37571861-D50490E1-AF2E-4A4B-B5F8-6E8D0EEC6A87Q38205581-A6A1F239-7367-4FAB-8135-145ED1FE291EQ38258643-381143B2-5985-4A72-B87C-4B6FA5E3B285
P2860
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The effect of empagliflozin on ...... ated type 1 diabetes mellitus.
@en
The effect of empagliflozin on ...... ated type 1 diabetes mellitus.
@nl
type
label
The effect of empagliflozin on ...... ated type 1 diabetes mellitus.
@en
The effect of empagliflozin on ...... ated type 1 diabetes mellitus.
@nl
prefLabel
The effect of empagliflozin on ...... ated type 1 diabetes mellitus.
@en
The effect of empagliflozin on ...... ated type 1 diabetes mellitus.
@nl
P2093
P2860
P356
P1476
The effect of empagliflozin on ...... ated type 1 diabetes mellitus.
@en
P2093
Bruce A Perkins
David Zi Cherney
Hans-Juergen Woerle
Maximilian von Eynatten
Nima Soleymanlou
Nora Fagan
Ronnie Har
Uli C Broedl
P2860
P2888
P356
10.1186/1475-2840-13-28
P407
P577
2014-01-29T00:00:00Z
P5875
P6179
1012393683